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Abstract:
Background:
Giant cell arteritis is the commonest form of medium-to-large vessel vasculitis, requiring long-term corticosteroid therapy. The short- and long-
term side effects of corticosteroids are many, including weight gain,  psychological effects,  osteoporosis,  cardiometabolic complications,  and
infections.
Materials and Methods:
Various agents used in place of or in combination with corticosteroids to reduce corticosteroid-related side effects were reviewed. However,
considerable  variation  in  practice  was  identified  giving  unclear  guidance.  This  review  included  the  most  recent  evidence  on  methotrexate,
mycophenolate mofetil, azathioprine, cyclophosphamide, abatacept, and tocilizumab
Results and Discussion:
Also discussed are encouraging results with tocilizumab in GCA patients. Amongst the agents available for steroid-sparing effects, tocilizumab
demonstrated the most robust data and is consequently recommended as the agent of choice for steroid-sparing, for remission induction, remission
maintenance, and treating relapsing and refractory cases of GCA.
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1. INTRODUCTION
Giant  Cell  (temporal)  Arteritis  (GCA)  is  a  chronic,
systemic  vasculitis,  with  a  distinct  tropism  for  large  and
medium-sized arteries with well-developed elastic membranes.
The  epidemiology  of  GCA  suggests  striking  differences  in
disease risk among ethnic groups, with the highest incidence
rates  found  in  Scandinavian  and  other  people  of  Northern
European descent, irrespective of their place of residence [1 -
5]. Globally, the incidence of GCA is around 27 per 100,000 in
persons  over  50  years  of  age  [6].  Corticosteroids  are  the
mainstay of therapy. Prompt diagnosis and initiation of therapy
is critical to prevent complications such as partial visual loss or
blindness  and  other  vascular  complications  [7  -  11].  The
average duration of corticosteroid therapy in GCA is 2-3 years,
although lifelong treatment may be required in some patients
[8, 12 - 15].
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School  of  Pharmacy,  WV1  1LY,  UK;  Email:  hana.morrissey@wlv.ac.uk;
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Long-term  corticosteroid  use  (3-6  months  or  more)  is
potentially  associated  with  treatment-related  Adverse  Events
(AEs),  however,  the  incidence  and  severity  are  commonly
dependent  on  a  combination  of  the  daily  dose  and  regimen
cumulative  dose  [15  -  18].  These  AEs  include  skin,
gastrointestinal,  ophthalmological,  skeletal,  adrenal,  cardio-
metabolic,  and  neuropsychiatric  complications  [13,  17,  19].
The  corticosteroid-related  AEs  patients  and  rheumatologists
consider  the  most  worrisome  include  weight  gain,  psycho-
logical effects, osteoporosis, and infections [20].
Given the substantial morbidity associated with long-term
corticosteroid  therapy,  guidelines  (e.g.,  from  the  European
league against  rheumatism [EULAR] and British  Society  for
Rheumatology) recommend that steroid-sparing agents should
be used [21], but as evidence is limited, there are variations in
the treatment strategy and no specific guidance available about
the agent choice for this diverse group of patients.
This critical review of the literature examines evidence on
agents that, if used may reduce the required steroid dose or the
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duration  of  steroids  treatment  and  decrease  the  frequency
and/or  intensity  of  patient  experienced  side  effects.
2. MATERIALS AND METHODS
The databases searched were; Medline®, Cochrane library
and EMBASE® using the keywords <steroid sparing effects>,
<methotrexate>,  <mycophenolate  mofetil>,  <cyclophos-
phamide>,  <azathioprine>,  <anti-TNF  agents>,  <abatacept>,
<selective T cell co-stimulation modulator> and <tocilizumab>
and <Giant Cell Arteritis>. The limits applied were from 2000
onwards  and  articles  in  the  English  language,  and  adult
population.  Relevant  natural  language  and  controlled
vocabulary terms were selected and combined. Where possible,
articles  were  restricted  to  systematic  reviews,  RCTs  or  case
series.
3. RESULTS AND DISCUSSION
3.1.  Variations  in  the  Optimal  Treatment  Strategies  for
GCA
In a large, representative cohort of real-world patients seen
in routine clinical practice of rheumatologists across the United
States of America, treatment patterns were reviewed using data
from  electronic  medical  records  and  other  sources  in  an
ongoing and continuous updating manner. These patients met
the  definition  of  at  least  two  GCA-related  diagnosis  codes
within a 1-year period, between 2013 and 2016. Amongst 1567
patients with a mean age of 72+10 years, 78% were Caucasian
and  78%  were  females.  The  mean  follow-up  period  was  24
months  with  an  average  of  12  Rheumatology  clinic  visits.
There  were  14%  of  all  patients  treated  with  more  than  one
agent  concurrently,  and  85%  received  corticosteroids.  This
study demonstrated that there was wide variation in treatment
practices where 22% of patients treated with methotrexate, 8%
with  hydroxychloroquine,  5%  with  aspirin,  5%  with
tocilizumab, and 3.5% with azathioprine [6]. This also reflects
the  lack  of  clarity  around  the  value  of  additional  steroid-
sparing  agents  to  avoid  [6]  corticosteroids.
3.2. Relapsing and Refractory GCA
The traditional view of GCA as a corticosteroid-responsive
disease  is  not  always  accurate  or  predictable;  a  spectrum  of
severity  and  extent  exists.  In  observational  cohort  studies,
relapses  were  reported  in  34-62%  of  patients,  with  15-20%
achieving  long-term sustained  remission  with  corticosteroids
alone [22]. Based on treatment response, GCA patients can be
divided into four subgroups; in-remission, relapsed, refractory,
and corticosteroid intolerant [3]. The last three groups exhibit
the greatest unmet need for adjunctive therapy [22]. A critical
review of the literature published in Clinical and Experimental
Rheumatology [23] revealed five case series with large cohorts.
These  suggested  that  40-48%  of  GCA  patients  require
additional immunosuppressive agents to achieve remission and
to taper their corticosteroid intake.
3.3. Methotrexate and Steroid-Sparing Effect
Methotrexate (MTX) efficacy and safety was evaluated in
patients with GCA enrolled in three randomized clinical trials.
These reported inconsistent efficacy, but reductions in relapse
rate  and  in  overall  corticosteroids  exposure  [24  -  26].  In  a
meta-analysis of individual patient data from these trials, it was
found that adjunctive low-dose MTX reduced both relapse risk
and  corticosteroids  exposure,  though  the  frequency  and
severity of AEs were not reduced [27, 28].  Adjunctive MTX
may reduce cumulative corticosteroids doses by 20% [25] and
relapses by 35% (28) in GCA. Similar beneficial effects were
observed  to  reduce  corticosteroids  dose  and  a  reduction  in
relapses [23].  Based on a systematic analysis of clinical  trial
data,  the  use  of  MTX  as  a  steroid-sparing  strategy  may  be
considered for patients at high risk for corticosteroid-induced
AEs at disease outset. It may also be useful for patients whose
disease course is protracted and who are at risk for recurrent
relapses and corticosteroid-induced AEs [29, 30].
3.4. Mycophenolate Mofetil
In  a  retrospective  study  (n=65  GCA  patients),  patients
were  divided  into  3  treatment  groups;  prednisolone  alone,
prednisolone  with  methotrexate,  and  prednisolone  with
mycophenolate (MMF). No significant difference was shown
between  the  groups.  The  study  concluded  that  MMF  is  as
effective as MTX and prednisolone alone in the treatment of
Large  Vessel  Vasculitis  (LVV).  However,  the  patient  group
was  small  which  limits  the  generalisation  of  this  finding.
Additionally,  there  was  no  randomisation  to  the  treatment
group;  treatment  choice  was  based  on  clinician  preference.
There was potential bias in that patients perceived to be more
difficult  to  treat  may  have  been  given  MMF  or  MTX  in
addition to prednisolone, and there were a higher proportion of
patients with LVV compared to GCA in the MMF and MTX
treated groups [31 - 34].
3.5. Azathioprine
A two-centre retrospective study was designed to describe
the  use  of  azathioprine  in  GCA  and  to  evaluate  its  steroid-
sparing effect. Of the 28 patients included, 21 responded to the
combination of azathioprine and prednisolone [35]. At 1 year
of  follow-up  from  the  initiation  of  azathioprine  and  a  daily
dose of prednisone,  18 patients (64%) were still  in sustained
response,  asymptomatic,  and  showed  no  increase  in  acute
phase  response  laboratory  markers.  Three  patients  (11%)
experienced a relapse during azathioprine treatment. The mean
daily dose of prednisone was 25.4 mg at the time of initiation
of azathioprine, and 4.7 mg at 1 year of treatment, suggesting a
good  steroid-sparing  effect  [35].  Treatment  cessation  was
required in 7 out of 10 patients who experienced azathioprine-
related serious side effects. It was concluded that azathioprine
may  be  an  alternative  treatment  for  patients  with  GCA
requiring  prolonged  high  dose  corticosteroids  therapy  or
developing  severe  corticosteroid  related  side  effects  [35].
3.6. Cyclophosphamide
Data  from  19  patients  treated  with  cyclophosphamide
(CYC) were retrospectively analysed. In 15 of the 19 patients,
CYC had been administered after the failure of high doses of
corticosteroids,  or  experiencing  a  relapse  during  medium  to
high dose corticosteroids therapy, with or without MTX [36].
CYC was used as the initial treatment in corticosteroid naive
patients (4 of the 19 patients). All of the participants were also
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diagnosed  with  type  2  diabetes.  During  the  6-12  months
follow-up,  15  of  the  19  patients  remained  in  remission.
Corticosteroids were suspended in 6 of the 15 patients, and a
dose of  5 mg/day of  prednisone was continued in 9 patients.
Relapse  occurred  in  4  of  the  15  patients  who  sustained
remission,  usually  12  months  after  CYC  was  ceased.  The
cessation  or  reduction  of  their  corticosteroid  daily  dose  or
reduction to 5 mg/day of prednisone took place within the first
6 months of follow-up after the initiation of CYC in 10 of the
15  patients.  Ten  adverse  events  were  registered  in  nine
patients,  with  recovery  soon  after  the  suspension  of  CYC or
dose reduction [36]. However, one death occurred due to acute
hepatitis.  The  disappearance  of  inflammatory  infiltrate  was
demonstrated in one patient when temporal artery biopsy was
repeated  3  months  after  CYC therapy.  This  study  concluded
that CYC could represent a useful option for patients requiring
prolonged medium- to high-dose of corticosteroid therapy and
at high risk of corticosteroids-related side effects (36).
3.7.  Anti-TNF Agents and their Steroid-Sparing Effect in
GCA
A  systematic  review  [37]  was  conducted  to  evaluate  the
efficacy and safety of infliximab and etanercept in LVV. This
review concluded that infliximab was not more effective than
corticosteroids  in  inducing remission in  GCA patients,  but  it
was effective in inducing remission and in steroid-sparing in
corticosteroid  refractory  Takayasu’s  arteritis.  The  review
concluded that etanercept has a role as a steroid-sparing agent
in  GCA with  corticosteroid  related  sever`1`e  adverse  effects
and  is  effective  in  inducing  remission  in  corticosteroid
refractory  GCA  [37].
3.8. Abatacept (Selective T cell Co-Stimulation Modulator)
and Steroid-Sparing in GCA
Abatacept,  a  selective  T  cell  co-stimulation  modulator
[38],  was  recently  evaluated  in  a  multicentre,  randomized,
double-blind  (phase  2)  trial  of  49  patients  with  GCA  who
received  a  standardized  prednisone  tapering  regimen  [20].
Patients’ selection criteria were temporal artery abnormality, a
biopsy demonstrating vasculitis, and characteristic changes of
large-vessel  stenosis  or  aneurysm  on  arteriography.
Additionally,  those with large-vessel  involvement underwent
MRI  of  the  aorta  and  branches  initially  and  at  6-month
intervals. At 12 months, the relapse-free rate was significantly
higher in the abatacept group than in the placebo group (48 vs
31%; P  = 0.049),  and a longer median duration of remission
was achieved with abatacept (9.9 vs  3.9 months;  P  = 0.023).
Despite  the  small  number  of  patients  with  large-vessel
involvement in this study population, the findings suggest that
abatacept may be an efficacious treatment option for reducing
relapse in patients with GCA, but comparative studies will be
required to determine its place in therapy.
3.9.  IL-6R Antagonist  (Tocilizumab) and Steroid-Sparing
Effect in GCA
Interleukin (IL)-6 contributes to the pathogenesis of GCA
and  represents  a  possible  target  for  therapy.  A  retrospective
study of 12 patients, with relapsing GCA history, were treated
with monthly infusions of the IL-6 receptor (IL-6R) antagonist
tocilizumab  (TCZ).  The  average  daily  prednisone  dose
decreased from 24 mg (95% CI 15-33.5)  at  the time of  TCZ
initiation  to  7.3  mg  (95%  CI  0.7-14)  by  the  time  of  last
evaluation (P = 0.01) [39]. The mean follow-up of this cohort
since  diagnosis  was  37  months.  Out  of  all  the  patients  who
received  TCZ,  7  patients  were  in  disease  remission  until  the
end of follow-up for a mean time of 17.5 months (range 8-26),
and  5  patients  experienced  a  flared  after  an  average  of  11
months of therapy (range 2-25). It was concluded that TCZ led
to a significant decrease in the flare rate and requirement for
corticosteroid  use  in  the  study  sample.  These  findings
supported that TCZ is a steroid-sparing agent during treatment
and  in  GCA  remission  [39,  40].  GiACTA,  a  randomized,
double-blind,  placebo-controlled  trial,  evaluated  TCZ
effectiveness  in  achieving  sustained,  corticosteroid  -free
remission. This was the first trial to employ a blinded, variable-
dose corticosteroid-tapering regimen [38]. The study concluded
that TCZ was not only highly effective in maintaining disease
remission induced by the combination of TCZ and prednisone,
but also that IL-6R blockade has a pronounced steroid-sparing
effect for patients [41]. The trial had 4 arms: 1) TCZ SC 162
mg weekly plus 6-month prednisone taper; 2) TCZ SC 162 mg
every other week plus 6-month prednisone taper; 3) prednisone
only  at  6-month  taper;  and  4)  prednisone  only  at  12-month
taper. Remission was sustained in 56% of the patients treated
with TCZ for 52 weeks in the weekly group and in 53% in the
‘every  other  week’  groups,  as  compared  with  14%  in  the  6
months  prednisone  taper  group  and  18%  in  the  12  months
prednisone taper group (P<0.001 for the comparisons of either
TCZ treatment with prednisone only groups). Serious adverse
events  occurred  in  15%  of  the  patients  in  the  group  that
received TCZ weekly, 14% of those in the group that received
TCZ every  other  week,  22% in  the  prednisone  6-moth  taper
group,  and  25%  in  the  12  months  prednisone  taper  group.
Anterior ischemic optic neuropathy developed in one patient in
the group that received TCZ every other week [31].
Table 1 summarizes all agents used for steroid-sparing and
the type of evidence available and recommendation for steroid-
sparing in GCA.
Table 1. Agents used for steroid-sparing in GCA treatments.
Serial
No.
Steroid Sparing Agent Levels of
Evidence
Recommendation as a Steroid-Sparing Agent in GCA
1 Methotrexate IB Second line agent
2 Mycophenolate IIIC Third line agent
3 Azathioprine IIIC Third line agent
4 Cyclophosphamide IIIC Third line agent
5 Anti-TNF agents IB Etanercept can be used as second-line agent for induction of remission
for corticosteroid refractory GCA)
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Serial
No.
Steroid Sparing Agent Levels of
Evidence
Recommendation as a Steroid-Sparing Agent in GCA
6 Abatacept (Selective T-cell co-stimulation
modulator)
IB Can be an option as Third-line but larger studies required
7 Tocilizumab (IL6R-antagonist) IA First line agent (most robust evidence available)
*Levels of evidence: I-Systematic review of all relevant RCT’s or an n=1RCT, II-Randomised trial or observational study with dramatic effect, III-Non-randomised
controlled cohort/follow up study(observational), IV- Case-series, case-control studies, or historically controlled studies, V- mechanism-based reasoning (expert opinion,
based on physiology, animal or laboratory studies).
*Grades: A- consistent level I studies, B- Consistent level II or III studies or extrapolations from level I studies, C- level IV studies or extrapolations from level 2 or 3
studies, D- level V evidence or troubling inconsistent or inconclusive studies of any level.
CONCLUSION AND RECOMMENDATION
At  the  time  of  writing,  there  was  no  British  Society  for
Rheumatology  guidance  although  this  may  be  revised  soon.
We analysed 13 studies (Table 2). There were two studies that
did not support the additive value of the use of steroid-sparing
agents. Five studies concluded that due to their small sample
size, they recommend conducting further larger studies and 11
studies concluded that there was significant value to the use of
steroid-sparing  agents  in  side-effect  reduction  and  clinical
outcomes  improvement.
Considering  all  the  evidence  available  for  choosing  the
most appropriate steroid-sparing agent in GCA, a large number
of  studies  favoured  TCZ.  There  is  good  evidence  that  it  can





The next best agent for steroid-sparing effect appears to be
MTX. There is good quality evidence that supports the use of
MTX to reduce flares in relapsing GCA and help in reducing
the corticosteroid dose and adverse effects.
Amongst  anti-TNF  agents,  use  of  etanercept  can  be  an
option in  corticosteroid  refractory GCA to induce remission.
Abatacept,  a  selective  T  cell  co-stimulation  modulator  had
shown promise in reducing relapse in GCA in RCTs involving
a small number of GCA patients.
Immunosuppressants  like  azathioprine,  mycophenolate,
and cyclophosphamide may be used in refractory GCA or large
vessel vasculitis patients as third-line agents.
Table 2. List of studies included in the systematic review.




















Z. Su, V. Menon, R. Gliklich, T.
Brecht, “Treatment patterns in
Large vessel vasculitis (Giant cell
arteritis and Temporal arteritis):
Findings from a large
contemporaneous real world cohort
in US”, Arthritis and








The cohort included 1,567 patients with a mean age of
72 + 10 years, three quarters were Caucasian (78%)
and female (76%). Median follow up time was 24
months with a mean of 12 rheumatology ambulatory
encounters. Nearly a third of the cohort had a
concomitant diagnosis of polymyalgia rheumatica
(33%) and 17% had rheumatoid arthritis. A majority
of the patients had at least one erythrocyte
sedimentation rate (ESR) and C-reactive protein
(CRP) measurement. Median ESR at baseline was
21mm/hr (IQR: 8, 48) and median CRP was 1mg/L
(0.3, 4.0). Only 6% of patients had a documented
temporal artery biopsy. Patient reported pain scores
were available in 26% of the patients with a median
duration of 6 months between first and last assessment.
The majority of patients received glucocorticoids
(85%), 22% were treated with methotrexate, 8% with
hydroxychloroquine, 5% with aspirin, 5% with
tocilizumab and 3.5% with azathioprine; 14% were
treated with more than one drug concurrently.
 
(Table 1) contd.....
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Wagner, J. Loock, W. L. Gross,
“Does glucocorticosteroid-resistant
large-vessel vasculitis (giant cell
arteritis and Takayasu arteritis)
exist and how can remission be
achieved? A critical review of the
literature”, Clinical and
Experimental Rheumatology, vol






Sixty-four publications were found. Five case series
described large cohorts of patients with GCA (n=2) or
TA (n=3) showing that 40.8% to 48% of GCA patients
and 46% to 84% of TA patients require additional
immunosuppressive agents to achieve remission and
taper GC. Most were on biologic agents (mainly
infliximab, 24 publications/123 patients), followed by
methotrexate (MTX) (14/113), cyclophosphamide
(CYC) (9/27), azathioprine (AZA) (8/51), cyclosporine
A (CSA) (6/47), mycophenolate mofetil (MMF) (3/32),
leflunomide (LEF) (2/2), chlorambucil (1/1) and
antimalarials (1/36). There were also 2 case reports on
autologous stem cell transplantation. The distribution
of the two entities TA and GCA was as follows: MTX:
98% GCA, 2% TA; IFX: 26.8% GCA, 73.2% TA; CYC:
70.4% GCA, 29.6% TA; AZA: 100% GCA; LEF: 100%
TA; MMF: 100% TA; antimalarials: 100% GCA,
autologous stem cell transplantation: 100% TA. A
distinction between GC-resistant and GC-dependent
cases could not be made from the data available.
However, 50 (79%) of the publications described GC-
resistant cases. Whereas almost all case reports and
retrospective case series (with the exception of CSA)
revealed steroid-sparing effects, the 3 prospective
randomised trials and 2 open prospective controlled
trials on MTX gave conflicting results. However, a
recent meta-analysis which recalculated the original
data resulted in superiority of MTX after 24 months,
there were less relapses and lower GC doses in the
MTX group. The prospective controlled IFX trial
where IFX was randomised against placebo after GC-
induced remission of GCA did not show advantages for
IFX over GC alone for maintenance of remission. The
prospective controlled ETA trial, which comprised 17
GCA patients, showed small, non-significant
advantages but was too small to draw definite
conclusions.
G. S. Hoffman, M. C. Cid, D. B.
Hellmann, et al., “International
Network for the Study of Systemic
Vasculitides, A multicenter,
randomized, double-blind,
placebo-controlled trial of adjuvant
methotrexate treatment for giant
cell arteritis”, Arthritis and




RCT Ninety‐eight patients were enrolled. No significant
differences between treatment groups were noted with
regard to age, frequency of positive findings on
temporal artery biopsy (placebo 87%, MTX 79%), or
comorbidities at the time of enrollment. The median
dosage of MTX was 15 mg/week. The incidence of
treatment failure was comparable between groups
after 12 months: 57.5% in the MTX group failed
treatment (95% confidence interval [95% CI]
41.6–73.4%) compared with 77.3% in the placebo
group (95% CI 61.9–92.8%) (P = 0.26). In a Cox
regression analysis, MTX was not associated with a
reduced risk of treatment failure (relative risk 0.72;
95% CI 0.41–1.28). There were no significant
differences between groups with regard to abnormal
elevations of the erythrocyte sedimentation rate
following initial remissions, serious morbidity due to
GCA, cumulative CS dose, or treatment toxicity. In the
MTX group, there were fewer cases of GCA relapse
heralded by symptoms of isolated polymyalgia
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J. A. Jover, C. Hernandez-Garcia,
I. C. Morado, et al., “Combined
treatment of giant-cell arteritis
with methotrexate and prednisone.
A randomized, double-blind,
placebo-controlled trial”, Annals




RCT Twenty-one patients received prednisone and
methotrexate and 21 received prednisone and placebo.
The 2 groups were similar at baseline, with a mean
age of 78 years, a mean erythrocyte sedimentation rate
of 91 and 100 mm/h respectively, and a polymyalgia
rheumatica prevalence of 57% and 52% respectively.
One patient in the methotrexate group and 2 in the
placebo group were lost to follow-up. All patients
responded to initial treatment. Disease relapse
occurred in 9 patients (45%) in the methotrexate
group, compared with 16 patients (84%) in the placebo
group (p = 0.018). Moreover, fewer relapses involving
cranial symptoms occurred among patients in the
methotrexate group than among the control subjects (2
v. 7 patients, p = 0.06). The median duration of
prednisone treatment was significantly shorter in the
methotrexate group than in the placebo group (29 v. 94
weeks, p = 0.0016), resulting in a lower mean
cumulative dose of prednisone (4187 v. 5489 mg, p =
0.009). There was a trend toward a lower incidence of
diabetes mellitus (3 v. 7 patients), arterial
hypertension (12 v. 16 patients) and cushingoid
appearance (3 v. 6 patients) in the methotrexate group.
Three patients receiving methotrexate experienced
myelosuppression or mucositis that necessitated
withdrawal of the drug. Of these, 1 patient was not
taking folic acid supplementation and 2 had mild renal
impairment
R. F. Spiera, H. J. Mitnick, M.
Kupersmith, et al., “A prospective,
double-blind, randomized,
placebo-controlled trial of
methotrexate in the treatment of
giant cell arteritis (GCA)”, Clinical
and Experimental Rheumatology,
vol 19, pp 495-501, 2001.
n=21
patients
RCT Twenty-one patients were enrolled, 12 randomized to
methotrexate, 9 to placebo. Baseline characteristics
(age, height, weight, sedimentation rate, bone mineral
density, total corticosteroid dose prior to
randomization, and quality of life as measured by
SF-36 and function as measured by AIMS) were
comparable between groups.
At completion, there was no significant difference
between methotrexate-and placebo-treated patients
with regard to the cumulative corticosteroid dose
(6469 mg and 5908 mg respectively, p=0.6), number of
weeks to completion of steroids (68 and 60
respectively, p=0.5), time (weeks) to taper prednisone
to less than 10 mg prednisone/day (23 and 25
respectively, p=0.5), bone mineral density in lumbar
spine (p=0.2) or hip (p=0.4) at one year, or functional
status as measured by AIMS and quality of life as
measured by SF36. There was no late vision loss in
either group, and only one major treatment-responsive
relapse in a methotrexate-treated patient. There were
few major corticosteroid-related side effects and these
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A. D. Mahr, J. A. Jover, R. F.
Spiera, et al., “Adjunctive
methotrexate for treatment of giant
cell arteritis: an individual patient
data meta-analysis”, Arthritis and








The combined data set comprised 161 patients, of
whom 84 received MTX and 77 received placebo. The
mean duration of follow-up was 54.7 weeks (SD 39.2
weeks). Hazard ratios (HRs) for a first and second
relapse of GCA were 0.65 (P = 0.04) and 0.49 (P =
0.02), respectively, in patients receiving MTX as
compared with patients receiving placebo.
Accordingly, a predicted 3.6 individuals (95%
confidence interval [95% CI] 2.2–56.8) and 4.7
individuals (95% CI 3.3–21.9) need to be treated with
MTX to prevent the occurrence of one first or one
second relapse, respectively, up to 48 weeks. Use of
MTX resulted in a reduction in the corticosteroid
cumulative dose by 842 mg within 48 weeks (P <
0.001). Moreover, MTX treatment was associated with
a higher probability of achieving sustained
discontinuation of corticosteroids for ≥24 weeks (HR
2.84, P = 0.001). Dropout rates and occurrence of
adverse events did not differ between treatment groups.
F. Buttgereit, C. Dejaco, E. L.
Matteson, B. Dasgupta,
“Polymyalgia rheumatica and giant
cell arteritis: a systematic review”.
Journal of American Medical












Twenty randomized clinical trials for therapy (n =
1016 participants) and 30 imaging studies for
diagnosis and/or assessing response to therapy (n =
2080 participants) were included. The diagnosis of
PMR is based on clinical features such as new-onset
bilateral shoulder pain, including subdeltoid bursitis,
muscle or joint stiffness, and functional impairment.
Headache and visual disturbances including loss of
vision are characteristic of GCA. Constitutional
symptoms and elevated inflammatory markers (>90%)
are common in both diseases. Ultrasound imaging
enables detection of bilateral subdeltoid bursitis in
69%of PMR patients. In GCA, temporal artery biopsy
remains the standard for definitive diagnosis.
Ultrasound and magnetic resonance imaging (MRI) of
large vessels revealing inflammation-induced wall
thickening support the diagnosis of GCA (specificity
78%-100% for ultrasound and 73%-97%for MRI).
Glucocorticoids remain the primary treatment, but the
optimal initial dose and tapering treatment regimens
are unknown. According to consensus-based
recommendations, initial therapy for PMR is
prednisone, 12.5 to 25mg/day or equivalent, and 40 to
60mg/day for GCA, followed by individualized
tapering regimens in both diseases.
Adjunctive methotrexate may reduce cumulative
glucocorticoid dosage by 20%to 44%and relapses by
36%to 54%in both PMR and GCA. Use of tocilizumab
as additional treatment with prednisone showed a 2-to
4-fold increase in remission rates of GCA in a
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R. Smith, K. P. Kuet, R. Kilding,
M. Akil, J.Maxwell., “A
comparison of the effectiveness of
mycophenolate mofetil or
methotrexate in combination with
prednisolone versus prednisolone
alone in the treatment of large
vessel vasculitis”, Annals of the







65 patients were included in the study, 41 with GCA
and 24 LVV. 49 were female and 16 male. Mean age at
diagnosis was 68; range 21 to 87. 37 patients were
treated with prednisolone alone; 35 had GCA and 2
LVV. 20 were treated with MMF and prednisolone; 4
with GCA and 16 LVV. 8 were treated with MTX and
prednisolone; 2 had GCA and 6 LVV. The AOC for
prednisolone and CRP were not normally distributed
across the cohort, and non-parametric methods were
therefore used for comparisons. Median AOC
prednisolone dose for the prednisolone only group was
68.0, (interquartile range (IQR) 17.7, n=37), for the
MMF treated group 70.8 (IQR 28.7, n=20) and for the
MTX treated group 67.8 (IQR 20.4 n=8). Median AOC
CRP was highest in the group treated with
prednisolone alone (58.9, IQR 34.5) compared to
MMF (43.8, IQR 26.5) and MTX (49.3 IQR 67.5) but
there were no statistical differences between median
AOC prednisolone dose or CRP in either the
unadjusted or regression models.
S. Sciascia, D. Piras, S Baldovino,
et al.,, “Mycophenolate mofetil as
steroid sparing treatment for
elderly patients with giant cell
arteritis: Report of three cases”,
Aging Clinical and Experimental




All three patients showed clinical benefit, and were
also able to taper steroid use to a more rapid regimen
compared with the recently suggested steroid reduction
approach. MMF was well tolerated, and no signs of
toxicity were observed in a mean of 21.6 months
(12-29) of follow- up
A. S. Boureau, P. de Faucal, O.
Espitia, L. De Decker, C. Agard,
“Place of azathioprine in the
treatment of giant cell arteritis”,
Revue de Medecine Interne, vol







Of the 28 patients included, 21 responded to
azathioprine. At 1 year of follow-up after the initiation
of azathioprine, 18 patients (64%) were still in
sustained response, asymptomatic, without increase in
acute phase response laboratory markers, and with a
daily dose of prednisone<10 mg. Three patients (11%)
experienced a relapse during azathioprine treatment.
Mean daily dose of prednisone were 25.4 mg at the
time of initiation of azathioprine, and 4.7 mg at 1 year
of treatment, suggesting a corticosteroid-sparing effect
(P<0.001). Ten patients experienced azathioprine
serious side effects, leading to discontinuation of
treatment in seven cases.
L. Quartuccio, M. Maset, G. De
maglio, et al., “Role of oral
cyclophosphamide in the treatment
of giant cell arteritis”,








The efficacy of CYC was observed in 15 of the 19
patients, and remission was still present 6-12 months
after CYC suspension in 12 of the 13 patients. GCs
were suspended in 6 of the 15 patients, and they were
continued at a dose ≤ 5 mg/day of prednisone in all the
remaining responders. Relapse occurred in 4 of the 15
patients, usually >12 months after CYC suspension.
Suspension of GC daily dose or reduction to ≤ 5
mg/day of prednisone occurred within the first 6
months of follow-up after the beginning of CYC in 10
of the 15 patients. Ten adverse events were registered
in nine patients, with recovery usually soon after the
suspension of CYC or dose reduction.
However, one death occurred due to acute hepatitis.
Disappearance of the inflammatory infiltrate could be
demonstrated when temporal artery biopsy was
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L. Silva, E. Loza, V. M. Martínez-
Taboada, et al., “Biological
therapy for large vessel vasculitis:
A systematic review”, Seminars in
Arthritis and Rheumatism, vol 43,





Of 3447 citations, abstracts, and hand-searched
studies screened, 90 were included. Most of the studies
included ANCA-associated vasculitis (AAV) patients
and only a few included large vessel vasculitis (LVV)
patients. Rituximab was the most used agent, having
demonstrated efficacy for remission induction in
patients with AAV. A number of studies used different
anti-TNFα agents with contrasting results. A few
uncontrolled studies on the use of abatacept,
alemtuzumab, mepolizumab, and tocilizumab were
found.
S. H. Unizony, B. Keroack, J. H.
Stone, “Tocilizumab for the
treatment of giant cell arteritis:
Extended follow-up”, Presse





The mean follow-up of this cohort since diagnosis was
37 months (range 17–70). Eight subjects had failed at
least one immunosuppressant (methotrexate,
azathioprine, cyclophosphamide, infliximab,
adalimumab and etanercept), and four had
contraindications for the use of GC. TCZ (4mg/kg, n
=3 and 8mg/kg, n =9) was given for a mean period of
16 months (range 6–27). Before and during IL-6R
blockade, the patients experienced an average of 2.7
(95% CI 2–3.5) and 0.6 (95% CI 0–1.2) disease
exacerbations per year, respectively (P =0.0006). The
mean daily prednisone dose of the cohort decreased
from 24mg (95% CI 15–33.5) at the time of TCZ
initiation to 7.3mg (95% CI 0.7–14) by the time of last
evaluation (P =0.01). On TCZ, 7 subjects maintained
disease remission until the end of follow-up for a mean
time of 17.5 months (range 8–26), and 5 patients flared
after an average of 11 months of therapy (range 2–25).
The mean prednisone dose at the time of disease flare
in these 5 patients was 4.5mg/day. One subject
relapsed after TCZ discontinuation. Currently, 5
patients take 5mg/day of prednisone or less, and 3
patients are off GC. Adverse effects attributable in part
to TCZ in this series included leucopenia (n =5),
transaminitis (n =8), and pneumonia (n =1). Autopsy
on one patient who died from an unrelated cause
revealed persistent vasculitis.
J. H. Stone, K. Tuckwell, S.
Dimonaco S et al., “Trial of
tocilizumab in giant-cell arteritis”,
The New England Journal of




RCT Sustained remission at week 52 occurred in 56% of the
patients treated with tocilizumab weekly and in 53% of
those treated with tocilizumab every other week, as
compared with 14% of those in the placebo group that
underwent the 26-week prednisone taper and 18% of
those in the placebo group that underwent the 52-week
prednisone taper (P<0.001 for the comparisons of
either active treatment with placebo). The cumulative
median prednisone dose over the 52-week period was
1862 mg in each tocilizumab group, as compared with
3296 mg in the placebo group that underwent the 26-
week taper (P<0.001 for both comparisons) and 3818
mg in the placebo group that underwent the 52-week
taper (P<0.001 for both comparisons). Serious adverse
events occurred in 15% of the patients in the group
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that received tocilizumab every other week, 22% of
those in the placebo group that underwent the 26-week
taper, and 25% of those in the placebo group that
underwent the 52-week taper. Anterior ischemic optic
neuropathy developed in one patient in the group that
received tocilizumab every other week.
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